68 Scopus citations

Abstract

Purpose of Review: In this review, we discuss the most recent developments in gene-editing technology and discuss their application to adoptive T cell immunotherapy. Recent Findings: Engineered T cell therapies targeting cancer antigens have demonstrated significant efficacy in specific patient populations. Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have led to impressive responses in patients with B-cell leukemia and lymphoma. CTL019, or KYMRIAH™ (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies. As CART19 enters routine clinical use, improving the efficacy of this exciting platform is the next step in broader application. Summary: Novel gene-editing technologies like CRISPR-Cas9 allow facile editing of specific genes within the genome, generating a powerful platform to further optimize the activity of engineered T cells.

Original languageEnglish
Pages (from-to)522-529
Number of pages8
JournalCurrent Hematologic Malignancy Reports
Volume12
Issue number6
DOIs
StatePublished - Dec 1 2017

Keywords

  • Adoptive cell therapy
  • CRISPR-Cas9
  • Chimeric antigen receptor T cells (CART)
  • Gene-editing
  • Immunotherapy
  • PD-1
  • TALEN
  • Zinc-finger nucleases

Fingerprint

Dive into the research topics of 'Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer'. Together they form a unique fingerprint.

Cite this